Top ▲
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| Quaternary Structure: Complexes | 
| integrin αVβ3 | 
| Gene and Protein Information  | ||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference | 
| Human | 1 | 1048 | 2q32.1 | ITGAV | integrin subunit alpha V | |
| Mouse | 1 | 1044 | 2 49.33 cM | Itgav | integrin alpha V | |
| Rat | - | - | 3q24 | Itgav | integrin subunit alpha V | |
| Previous and Unofficial Names  | 
| CD51 | MSK8 | Vitronectin receptor subunit alpha | VNRA | VTNR | 
| Database Links  | |
| Alphafold | P06756 (Hs), P43406 (Mm) | 
| ChEMBL Target | CHEMBL3660 (Hs), CHEMBL4523628 (Mm), CHEMBL3430891 (Mm) | 
| DrugBank Target | P06756 (Hs) | 
| Ensembl Gene | ENSG00000138448 (Hs), ENSMUSG00000027087 (Mm), ENSRNOG00000004912 (Rn) | 
| Entrez Gene | 3685 (Hs), 16410 (Mm), 296456 (Rn) | 
| Human Protein Atlas | ENSG00000138448 (Hs) | 
| KEGG Gene | hsa:3685 (Hs), mmu:16410 (Mm), rno:296456 (Rn) | 
| OMIM | 193210 (Hs) | 
| Pharos | P06756 (Hs) | 
| RefSeq Nucleotide | NM_001144999 (Hs), NM_002210 (Hs), NM_008402 (Mm) | 
| RefSeq Protein | NP_002201 (Hs), NP_001138471 (Hs), NP_032428 (Mm) | 
| UniProtKB | P06756 (Hs), P43406 (Mm) | 
| Wikipedia | ITGAV (Hs) | 
                            Download all structure-activity data for this target as a CSV file  
                        
| Inhibitor Comments | ||
| Bexotegrast binds to αVβ6 with an IC50 of 5700 nM [1]. | 
| Antagonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 
 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| General Comments | 
| The αv integrins (especially αvβ6) have been identified as playing a key role in the development of idiopathic pulmonary fibrosis (IPF) [3]. Pan αv inhibitors are therefore being examined for clinical utlility as treatments for IPF. | 
1. Decaris ML, Schaub JR, Chen C, Cha J, Lee GG, Rexhepaj M, Ho SS, Rao V, Marlow MM, Kotak P et al.. (2021) Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res, 22 (1): 265. [PMID:34666752]
2. Hall ER, Bibby LI, Slack RJ. (2016) Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand. Biochem Pharmacol, 117: 88-96. [PMID:27501918]
3. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski PG et al.. (2013) Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med, 19 (12): 1617-24. [PMID:24216753]
4. Hutchinson JH, Halczenko W, Brashear KM, Breslin MJ, Coleman PJ, Duong LT, Fernandez-Metzler C, Gentile MA, Fisher JE, Hartman GD et al.. (2003) Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J Med Chem, 46 (22): 4790-8. [PMID:14561098]